Walleye Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Walleye Capital’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-400	Closed	-$23.5K	–	6142
2023 Q4	$23.5K	Buy	+400	New	+$22.5K	﹤0.01%	4450
2023 Q3	–	Sell	-5,400	Closed	-$195K	–	5475
2023 Q2	$195K	Buy	5,400 +4,300	+391%	+$177K	﹤0.01%	3102
2023 Q1	$40.9K	Buy	+1,100	New	+$49.5K	﹤0.01%	3249
2019 Q3	–	Sell	-4,700	Closed	-$484K	–	2345
2019 Q2	$484K	Sell	4,700 -8,800	-65%	-$685K	0.05%	503
2019 Q1	$990K	Buy	+13,500	New	+$918K	0.16%	168

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Walleye Capital's MRTX Position: Q1 2024 in Review

Walleye Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 24,413 shares — an estimated $1.43M sold.

Walleye Capital first reported a position in MRTX in Q2 2019 and held it in 8 quarters. The position peaked at $6.78M in Q1 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Walleye Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Walleye Capital sold 24,413 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.43M.
Walleye Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2019 and held it in 8 quarters.
Walleye Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $6.78M in Q1 2023.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Walleye Capital's 13F filing for Q1 2024, filed 15 May 2024.